The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Exploring effects of MEK inhibition in tumor microenvironment in non-small cell lung cancer (NSCLC) pre-clinical models.
 
Tarik Silk
No Relationships to Disclose
 
Hyejin Choi
No Relationships to Disclose
 
Jiehui Deng
No Relationships to Disclose
 
Stephane Pourpe
No Relationships to Disclose
 
Kwok-Kin Wong
Stock and Other Ownership Interests - G1 Therapeutics
Honoraria - Array BioPharma; AstraZeneca; Genocea Biosciences; Janssen Oncology; Lilly; Novartis; Ono Pharmaceutical
Research Funding - AstraZeneca; Gilead Sciences; GlaxoSmithKline; Janssen Oncology; Janssen Oncology; Janssen Oncology; Janssen Oncology (Inst); Janssen Oncology (Inst); Lilly
 
Taha Merghoub
No Relationships to Disclose
 
Jedd D. Wolchok
Stock and Other Ownership Interests - Adaptive Biotechnologies; Imvaq Therapeutics; Potenza Therapeutics; Serametrix; Tizona Therapeutics, Inc.; Trieza Therapeutics
Honoraria - Regeneron
Consulting or Advisory Role - Adaptive Biotechnologies; Amgen; Ascentage Pharma; Beigene; Bristol-Myers Squibb; Chugai Pharma; FSC Pediatrics; Genentech; Lilly; MedImmune; Merck; Ono Pharmaceutical; Polaris; Polynoma; Potenza Therapeutics; Sellas Life Sciences; Tizona Therapeutics, Inc.
Research Funding - Bristol-Myers Squibb (Inst); F-Star Therapeutics; Genentech/Roche (Inst); Incyte (Inst); Leap Therapeutics (Inst); MedImmune (Inst); Merck Sharp & Dohme (Inst)
Patents, Royalties, Other Intellectual Property - I am a co-inventor on a patent for use of oncolytic Newcastle Disease virus.; I am a co-inventor on an issued patent for DNA vaccines for treatment of cancer in companion animals.
Travel, Accommodations, Expenses - Amgen; Astellas Pharma; Bristol-Myers Squibb; Chugai Pharma; Janssen; Ono Pharmaceutical; Roche